Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose Presents Highlights from Corporate Update and KOL Event
09:30pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
08:15pm, Tuesday, 31'st May 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript
10:00pm, Monday, 09'th May 2022
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. William G. Rice – Chairman, President and Chief Executive Officer Dr. Rafael B
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
11:30am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
11:30am, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
07:30am, Tuesday, 03'rd May 2022
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hig
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
08:10pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
11:30am, Monday, 25'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase i
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
07:30am, Monday, 25'th Apr 2022
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inh
Aptose Announces Executive Management Changes
11:00am, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
─ Appoints Philippe Ledru as Chief Commercial Officer ─
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
11:30am, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing
Aptose to Present at Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference
07:30am, Thursday, 31'st Mar 2022
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results - Earnings Call Transcript
08:24pm, Tuesday, 22'nd Mar 2022
Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results - Earnings Call Transcript
Aptose Reports Results for the Fourth Quarter and Full Year 2021
08:01pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
- HM43239 clinical remission at 120mg expands list of potential treatable AML populations -
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
12:31pm, Tuesday, 22'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer
Merck & Co., Inc. (NYSE: MRK) s
